Nucleus RadioPharma Appoints Kathy Spencer-Pike as CCO

Nucleus RadioPharma, the pioneering radiopharmaceutical business, has appointed Kathy Spencer-Pike as Chief Commercial Officer in a deliberate move to strengthen its leadership team. Ms. Kathy is ready to play a significant role in advancing Nucleus RadioPharma's expansion, with over two decades of experience in Fortune 50 environments and a solid track record in fast-paced growth and startup firms.

Ms. Kathy brings a lot of commercial expertise to her new position, having previously held significant roles at industry heavyweights such as McKesson, Novo Nordisk, Sanofi, and Pfizer. Her responsibilities include leading Nucleus RadioPharma's expansion strategies following the company's successful oversubscribed $56M Series A investment round in October.

Nucleus RadioPharma CEO Charles S. Conroy expressed excitement about the hiring, citing Kathy's demonstrated track record of increasing organizational value and her ability to lead high-performing teams. Ms. Kathy’s hiring follows a string of recent C-Suite hires, indicating the company's commitment to building a seasoned leadership team.

Prior to joining Nucleus RadioPharma, Kathy was Chief Sales Officer at McKesson, where she was responsible for generating significant business development and merging three heritage divisions into a single commercial entity. Her success extends to her time as Novo Nordisk's VP, Commercial Leader, where she exceeded revenue targets by expertly planning, implementing, and executing market and sales strategies.

Ms. Spencer-Pike is a devoted champion for Diversity, Equity, and Inclusion (DE&I), having led the biggest US-based Women's Employee Resource Group at Pfizer and Novo Nordisk. This appointment demonstrates Nucleus RadioPharma's dedication to speeding expansion and providing life-saving medications to cancer patients throughout the world.